Enzastaurin and fragile histidine triad (FHIT)-increasing agents for the treatment of pulmonary hypertension
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsEdda Spiekerkoetter, Svenja Dannewitz Prosseda, Xuefei Tian, Purvesh Khatri
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treatment or prevention of pulmonary hypertension and emphysema using agents that increase activity of FHIT, such as Enzastaurin. Included are methods for using levels of FHIT and/or BMPR2, and checking for mutations in FHIT and/or BMPR2, to select patients for treatment or to monitor effectiveness of treatment. The invention is based on evidence that Enzastaurin prevents and reverses pulmonary hypertension induced in animal model systems, and that it acts by up-regulation of FHIT and/or BMPR2.
Claims13
A method for preventing and/or treating pulmonary hypertension and/or emphysema in a subject in need of prevention and/or treatment, which method comprises administering an effective amount of Enzastaurin, wherein the effective amount of Enzastaurin is administered to a subject to reduce systemic blood pressure of said subject or the treatment reduces meanPAP pulmonary artery pressure (PAPm) below 20 mmHg, PVR below 3 WU, and/or PAWP (pulmonary artery wedge pressure) above 15 in said subject.
Dependencies are inferred from the claim text.